title: [High-dose chemotherapy (HDCT) with peripheral blood stem cell transplantation (PBSCT) in ovarian cancer patients with poor prognosis].
abstract: Platinum is a key drug in ovarian cancer chemotherapy. Through combination with peripheral blood stem cell transplantation (PBCST), up to three times the usual carboplatin dose (1,200 mg/m2) may be given. If granulocyte colony stimulating factor (G-CSF) is added to the PBSCH harvest and apheresis is performed twice when the leukocyte count exceeds 10,000/microliters 14 days before and after the platinum-based chemotherapy, the necessary hematopoietic stem cell collection for bone marrow reconstitution can be done. This treatment proves most effective when the initial treatment is under way and it is used as a consolidation therapy for minimum residual disease very similar to PCR or for PCR itself. Forthcoming investigation should determine what impact this therapeutic approach will have on longer survival, or whether it will contribute to treatment of an ovarian cancer with a poor prognosis, for example, when the residual tumor measures more than 2 cm in diameter. Moreover, what results can be expected if one uses effective ip chemotherapy with the standard dose in conjunction with the PBSCT-HDCT combination? Especially, if one can contact the residual tumor in the intraperitoneal cavity most likely to have a recurrence with a drug at an extremely high concentration, enabling a massive dose to the intraperitoneal cavity comparable to the standard dosage by vas internal administration with equivalent blood concentration, distant metastases may also be prevented.
authors.affiliation: Dept. of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Hayakawa
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: A
authors.initials: A
authors.lastname: Yajima
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011379:Prognosis
chemical_list: D005047:Etoposide; D016190:Carboplatin; D002945:Cisplatin